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Introduction
The ACR recommendations for the treatment of Juve-
nile Idiopathic Arthritis (ACR-JIA) were published in
2011 with the aim of providing an evidence-based thera-
peutic pathway for effective JIA treatment.
Objectives
Our aim was to determine the feasibility of applying
ACR-JIA to a real-life paediatric JIA cohort and to eval-
uate the treatment pathway of those children.
Methods
We conducted a retrospective analysis of a single-centre
paediatric JIA cohort. This included a review of the
patient case notes, radiology and drug monitoring data
of all children with JIA diagnosed with multi-joint (5 or
more joint) disease in the 2 years since ACR-JIA were
published.In total, 35 patients fulfilled ILAR criteria for
the diagnosis of JIA since 2011: systemic arthritis (n=5),
polyarthritis (n=25) and extended Oligoarthritis (n=5).
Duration to Methotrexate and Etanercept treatments
was calculated, and the frequency of drug monitoring
noted.
Results
25 females and 10 males (median age at onset 13, range
1.5-15 years) were included in the evaluation. Median
age at disease onset for poly/extended oligoarthritis was
10 years (1.5-16), with a median of 12 joints (12-38)
active at presentation, and for the systemic group med-
ian age at onset was 6 years (2-7), with a median num-
ber of 6 active joints (2-10). 3 polyarthritis patients were
rheumatoid factor positive (0 extended oligoarthritis and
0 systemics). 22/30 patients with polyarthritis/extended
oligoarthritis followed the ACR recommendations for
treatment according to their disease severity, commen-
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Systemic Low 1 0 0 N/A N/A
N=5 Moderate 2 0 0
High 2 0 0
Polyarthritis & extended
oligoarthritis




N=30 Moderate 23 9 2
High 6 2 1
Unknown 1 0 0
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cing methotrexate therapy within a median of 6 weeks
(3-37) of diagnosis and etanercept (where relevant)
within a median of 7 months (3-24) of diagnosis.
7 patients did not follow ACR-JIA guidelines due to
experiencing excessive durations (for disease severity)
between diagnosis and commencing methotrexate or
etanercept treatment. One patient did not have suffi-
cient regular drug monitoring tests. All patients with
systemic arthritis followed the ACR-JIA recommenda-
tions for treatment and drug monitoring.
Conclusion
Overall, 27/35 patients followed the ACR-JIA recom-
mendations. This evaluation highlights the difficulty of
achieving rapid commencement of new JIA therapies
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